CrossrefInfokarte
An Updated Indirect Comparison of Elranatamab Versus a Real-World External Control Arm in Triple-Class Refractory Multiple Myeloma
Blood and Lymphatic Cancer: Targets and Therapy · 2025-06 · Volume 15 · 11-20
DOI: 10.2147/blctt.s516356 ↗Abstract
Kein Abstract verfügbar.
EUVIMED